Logistic regression analysis of predictors of purified protein derivative (PPD) screening offer and completion among human immunodeficiency virus (HIV)-infected patients*
| Characteristics | PPD screening offer# | PPD screening completion¶ | ||||||||
| Subjects offered PPD | Subjects not offered PPD | OR | 95% CI | p-value | Subjects completing PPD | Subjects non-completing PPD | OR | 95% CI | p-value | |
| Subjects n | 1445 | 185 | 1209 | 236 | ||||||
| Years of education | ||||||||||
| <6 | 319(22.1) | 55(29.7) | 1.00 | 256(21.2) | 63(26.7) | 1.00 | ||||
| 6–8 | 682(47.2) | 92(49.8) | 1.68 | 0.99–2.84 | ns | 564(48.6) | 118(50.0) | 1.67 | 1.10–2.51 | 0.01 |
| >8 | 444(30.7) | 38(20.5) | 1.55 | 0.86–2.78 | ns | 389(32.2) | 55(23.3) | 2.65 | 1.65–4.25 | <0.001 |
| AIDS diagnosis | ||||||||||
| No | 1315(91.0) | 160(86.5) | 1.00 | 1098(90.8) | 217(91.9) | 1.00 | ||||
| Yes | 130(9.0) | 25(13.5) | 0.30 | 0.16–0.58 | <0.001 | 111(9.2) | 19(8.1) | 1.36 | 0.75–2.46 | ns |
| Antiretroviral therapy | ||||||||||
| No | 1015(70.2) | 132(71.4) | 1.00 | 835(69.1) | 180(76.3) | 1.00 | ||||
| Yes | 430(29.8) | 53(28.6) | 1.59 | 1.03–2.45 | 0.04 | 374(30.9) | 56(23.7) | 1.49 | 1.01–2.18 | 0.04 |
Data are presented as n (%) unless otherwise stated
OR: odds ratio
CI: confidence interval
ns: nonsignificant
AIDS: acquired immune deficiency syndrome
*: Sex, age, origin, HIV transmission category, occupation, CD4+ cell count, time since first HIV-positive test, and clinical centres are included in the models
#: includes 1,630 patients for whom PPD screening was indicated
¶: includes 1,445 patients to whom PPD screening was offered